Solventum (SOLV) Q3 2025 earnings summary

Executive summary

• Achieved strong Q3 2025 performance with organic sales up 2.7% and reported sales up 0.7%, driven by growth in Dental Solutions, Health Information Systems, and MedSurg segments.

• Completed the sale of the Purification & Filtration business for ~$4 billion, generating ~$3.6 billion in net proceeds and a $1.5 billion pre-tax gain, with $2.7 billion applied to debt paydown.

• Launched the multi-year 'Transform for the Future' initiative targeting $500 million in annual cost savings over four years, with some reinvestment in growth.

• Transitioned to a standalone company post-spin-off from 3M, investing in separation and operational stand-up.

• Enhanced balance sheet flexibility and credit ratings through debt reduction and operational improvements.

Financial highlights

• Q3 2025 sales were $2.1 billion, up 2.7% organically and 0.7% reported year-over-year.

• GAAP net income surged to $1.27 billion, with diluted EPS at $7.22, mainly due to the business sale; adjusted EPS was $1.50.

• Adjusted operating income margin was 20.6%; gross margin was 55.8% (non-GAAP) and 54.2% (GAAP).

• Free cash flow was negative at $(22) million for Q3, reflecting divestiture and separation costs.

• Cash and cash equivalents increased to $1.64 billion as of September 30, 2025.

Outlook and guidance

• Raised full-year 2025 organic sales growth guidance to the high end of 2%-3%.

• Adjusted EPS guidance increased to $5.98–$6.08 for 2025.

• Free cash flow guidance revised to $150 million–$250 million due to the divestiture.

• The 'Transform for the Future' program targets $500 million in annual cost savings over four years.

• On track to achieve 2028 long-range plan goals of 4%-5% sales growth and 10% EPS CAGR.